Mark Shearman - Jun 14, 2021 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
EVP, Chief Scientific Officer
Signature
/s/ Mark S. Shearman
Stock symbol
EDIT
Transactions as of
Jun 14, 2021
Transactions value $
$0
Form type
4
Date filed
6/16/2021, 04:19 PM
Next filing
Dec 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Award $0 +32.7K $0.00 32.7K Jun 14, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EDIT Stock Option (right to buy) Award $0 +52.7K $0.00 52.7K Jun 14, 2021 Common Stock 52.7K $38.53 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 14, 2022 continuing through June 14, 2025.
F2 This option was granted on June 14, 2021 and is scheduled to vest over four years, with 25% of the shares to vest on June 14, 2022 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 14, 2025.